Showing results (1511-1520 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 7, 2021
TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathwaysAkihiro Miura, Hiroshi Sootome, Naoya Fujita, et al.
Investigational New Drugs|February 16, 2020
Evaluating the antitumor activity of sphingosine-1-phosphate against human triple-negative breast cancer cells with basal-like morphologyOmar Abuhussein, Jian Yang
Investigational New Drugs|February 20, 2020
Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort studyTao Li, Dong-Dong Jia, Li-Song Teng
Investigational New Drugs|March 9, 2020
Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancerK Esther Broekman, Marieke A J Hof, Daan J Touw, et al.
Investigational New Drugs|July 15, 2021
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancerChristian Kollmannsberger, Carolyn D Britten, Anthony J Olszanski, et al.
Investigational New Drugs|November 21, 2022
A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumorsNeeltje Steeghs, Melinda Pruis, Carla van Herpen, et al.
Investigational New Drugs|May 20, 2014
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell linesPatricia Izetti, Agnes Hautefeuille, Ana Lucia Abujamra, et al.
Investigational New Drugs|June 1, 2014
Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation studyGerald Falchook, Razelle Kurzrock, Launce Gouw, et al.
Investigational New Drugs|June 5, 2014
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancerMeng Zhao, Xueliang Pan, Rachel Layman, et al.
Investigational New Drugs|November 9, 2012
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinibGrace K Dy, Jeffrey R Infante, S Gail Eckhardt, et al.
Pageof 372